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gesting that cells present in this compartment post-BMT may be
composed of both migrants and a resident population. To mediate
resistance to PC engraftment, effector CD8 cells must ﬁrst sur-
vive conditioning and the BMT milieu. B6BALB.B mice irradiated
at 3, 6, and 9 Gy were analyzed 24 hours later for CD8 H60-
speciﬁc T cells in the spleen and BM. Tertramer cells were
clearly identiﬁed in both compartments showing dose-dependent
increases. Importantly, 5 days after HCT with 1  107 H60
congenic (or BALB.B) TCD BM, PC rejection was evident, as
indicated by nondetectable splenic CFU activity in recipients of
these allogeneic, but not syngeneic TCD-BM. Notably, tetramer
cells were again detected in BM and spleen. Interestingly, their
frequency was 3fold higher in the marrow (mean, 6%) than in the
splenic compartment (mean, 1.7%) in sensitized recipients of ei-
ther syngeneic or MiHA allogeneic BM. These increases are con-
sistent with the predicted survival advantage of CD8 memory T
cells due to elevated bcl-2 levels. However, resistance did not occur
in syngeneic recipients due to lack of activation of H60-speciﬁc T
cells. These studies conclusively demonstrate that an antigen-
speciﬁc CD8 T-memory population responsible for resistance sur-
vives allogeneic BMT and is present in bone marrow and spleen
where resistance is presumed to occur. Studies are underway to
functionally and molecularly characterize this MiHA antigen-spe-
ciﬁc population during ongoing resistance post-HCT.
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Absolute lymphocyte count (ALC) recovery to  500/l by day
15 post-autologous peripheral blood stem cell transplant (APB-
SCT) is associated with an improved overall and event-free survival
(EFS) for patients with non-Hodgkin’s lymphoma (NHL). The
beneﬁt of the ALC post-APBSCT is likely due to natural killer
(NK) cells, because patients who achieved a normal NK cell count
( 80/l) on day 15 post-APBSCT (day 15 NK) had an improved
EFS compared with those whose day 15 NK was low. Finally, the
day 15 ALC correlates to the infused autograft absolute lympho-
cyte count (A-ALC) and not with total CD34 dose. Thus we
hypothesized that a peripheral blood stem cell mobilization regi-
men would be ideal if it could mobilize CD34 cells, lymphocytes,
and NK cells. A pilot study was undertaken using a sequential
mobilization regimen of granulocyte colony-stimulating factor (G-
CSF) followed by aldesleukin. Patients received G-CSF at 10
g/kg/day, and stem cell collections began on day 5 or later, when
the peripheral blood (PB) CD34 cell count was  10/l. Once
stem cell collection was complete and a minimum of 2 106 CD34
cells/kg were collected, patients received 1 subcutaneous injection
of aldesleukin and underwent 1 further apheresis the next day
collect lymphocytes. The dose levels of aldesleukin were 0, 0.5, 1,
1.5, and 2  106 U/m2. Patients then underwent conditioning for
APBSCT and on day 0 received all of the apheresis product,
including the extra collection of lymphocytes. PB lymphocyte
counts and subset analysis were measured at baseline (before G-
CSF), pre-aldesleukin, 1 day post-aldesleukin, and day 15 post
APBSCT. A total of 43 patients with NHL were entered in the
study. Of these, 26 completed an adequate CD34 collection, re-
ceived aldesleukin, and underwent an extra apheresis. The results
of these 26 patients are presented. The median CD34 collected,
A-ALC, autograft NK collected (A-NK), day 15 ALC, and day 15
NK for each dose level are given. The median times to neutrophil
and platelet engraftment were 13 and 12 days, respectively. We
conclude that aldesleukin up-regulates NK cell numbers. Dose
level 3 resulted in the best NK cell apheresis collection, the highest
PB NK cell count post-aldesleukin, on day 15 NK, and on day 15
ALC. Only at this dose did all patients achieve a normal day 15 NK
cell count. A phase II study is proposed using a sequential regimen
of G-CSF followed by aldesleukin at a dose of 1.5  106/m2 to
conﬁrm these results. Successful lymphocyte and NK cell engraft-
ment post-APBSCT may become as important as neutrophil and
platelet engraftment post-APBSCT.
Dose
Level
IL-2
Dose
#
Patients CD34
Total
A-ALC
Total
A-NK
Day 15
ALC
Day 15
NK
0 0 5 7.36  106/kg 0.57  109/kg 0.09  109/kg 744/l 194/l
1 0.5  106 IU/m2 5 4.37  106/kg 0.47  109/kg 0.09  109/kg 310/l 92/l
2 1  106 IU/m2 5 4.87  106/kg 0.67  109/kg 0.10  109/kg 700/l 120/l
3 1.5  106 IU/m2 5 6.96  106/kg 0.38  109/kg 0.11  109/kg 1380/l 472/l
4 2  106 IU/m2 6 3.73  106/kg 0.43  109/kg 0.10  109/kg 787/l 192/l
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NKG2D is an activating receptor that is expressed onCD8T cells
and & T cells where it up-regulates activation through T-cell
receptor (TCR) costimulation. NKG2D is triggered by ligands that
are structurally related to major histocompatibility complex (MHC)-1
and expressed by tissues early in ontogeny, stress, and transformation.
The function of NKG2D on natural killer (NK) cells and CD8 T
cells is mediated by 2 distinct pathways of signaling through its
association withDAP10 andDAP12. One functionally distinct human
NKG2D isoform has been identiﬁed. In evaluating human NKG2D
gene expression by reverse-transcription polymerase chain reaction
(RT-PCR) in CD8T cells derived from 7 different donors, we
consistently observed 2 distinct bands differing by 218bp. Cloning and
sequencing of both PCR amplicons revealed a previously described
alternatively spliced NKG2D variant from inclusion of intron 6.
Intron 6 inclusion introduces a stop codon, resulting in a truncated
protein product lacking the entire extracellular domain. To determine
the functional consequences of truncated NKG2D expression, we
isolated and cloned both full-length and truncatedNKG2D into pRJ3
vectors. Human CD8 T cells were tranduced and directed against
human cell line targets in Cr51 cytotoxicity assays. We found that
expression of the full-length NKG2D resulted in a15% increase in
cytotoxicity, whereas expression of the truncated NKG2D resulted in
70% reduction in cytotoxicity. Results were compared to CD8 T
cells transduced with an empty vector. To further elucidate the role of
each NKG2D isoform, we coexpressed full-length and truncated
NKG2D with DAP-10 or DAP-12. Coexpression of full-length
NKG2Dwith either DAP10 orDAP12 resulted in a comparable 25%
cytotoxicity versus NKG2D alone. Coexpression of full-length and
truncated NKG2D also resulted in reduction of up to 65% coexpres-
sion of the truncated NKG2D isoform with DAP10 or DAP12 did
not alter the reduction in cytotoxicity observed with truncated
NKG2D alone.We also performed experiments usingmurine CD8
T cells with human cell line targets. Overexpression of full-length
NKG2D resulted in a  32% increase in cytotoxicity, whereas coex-
pression of full-length NKG2D and DAP10 resulted in a 42% in-
crease in cytotoxicity. Collectively, these results demonstrate that the
NKG2D isform lacking the extracellular domain unexpectedly inhib-
its cytotoxicity in human CD8 T cells. Also of interest is whether
variability in expression of the truncated NKG2D isoform inﬂuences
the cytotoxic potency of activated CD8 T cells expanded from
different donors.
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